Logo

Takeda Acquires Exclusive Worldwide License Rights for COUR's CNP-101 to Treat Celiac Disease

Share this

Takeda Acquires Exclusive Worldwide License Rights for COUR's CNP-101 to Treat Celiac Disease

Shots:

  • COUR to receive ~$420M milestone and royalties on sales of licensed products. Takeda exercised its option to acquire the exclusive global license to develop and commercialize TAK-101/CNP-101 following P-IIa proof-of-concept placebo-controlled study
  • In Dec’2015- Takeda and COUR collaborated to develop therapies for celiac disease- provided Takeda an exclusive option to acquire a WW license to the developed program and an option to collaborate up to three additional TIMP compounds
  • CNP-101/TAK-101 is an investigational immune modifying nanoparticle designed to induce tolerance to gluten in patients with celiac disease. The P-IIa POC study results demonstrated mean change from baseline in IFN-γ ELISpotSFUs (2.10 vs 17.57)- protection from intestinal mucosal damage with deterioration (0.18 vs 0.63)

Click here to­ read full press release/ article 

 Ref: Takeda | Image: Takeda


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions